1. Ali M, Aamir A, Diwan MN, Awan HA, Ullah I, Irfan M, De Berardis D. Treating Postpartum Depression: What Do We Know about Brexanolone? Diseases 2021; 9 (3).
2.
Anderson GD. Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach. Clin Pharmacokinet 2005; 44 (10): 989-1008.
3.
Andrade SE, McPhillips H, Loren D, Raebel MA, Lane K, Livingston J, Boudreau DM, Smith DH, Davis RL, Willy ME, Platt R. Antidepressant medication use and risk of persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf 2009; 18 (3): 246-52.
4.
Betcher HK, Wisner KL. Psychotropic Treatment During Pregnancy: Research Synthesis and Clinical Care Principles. J Womens Health (Larchmt) 2020; 29 (3): 310-18.
5.
Bhagwagar Z, Wylezinska M, Jezzard P, Evans J, Boorman EP, Matthews PM, Cowen PJ. Low GABA concentrations in occipital cortex and anterior cingulate cortex in medication-free, recovered depressed patients. Int J Neuropsychopharmacol 2008; 11 (2): 255-60.
6.
Bracken MB. SSRIs and autism: interpreting an umbrella review. Lancet Psychiatry 2019; 6 (11): 893.
7.
Brunton PJ. Neuroactive steroids and stress axis regulation: Pregnancy and beyond. J Steroid Biochem Mol Biol 2016; 160: 160-8.
8.
Da-Silva TG, Vasconcelos PF, Moura IGS. Uma abordagem atual da utilização de antidepressivos no manejo da depressão pós-parto, SMAD. Revista eletrônica saúde mental álcool e drogas 2021; 17: 101-8.
9.
Davanzo R, Copertino M, De Cunto A, Minen F and Amaddeo A. Antidepressant drugs and breastfeeding: a review of the literature, Breastfeed Med 2011; 6 (2): 89-98.
10.
Dubnov-Raz G, Juurlink DN, Fogelman R, Merlob P, Ito S, Koren G and Finkelstein Y. Antenatal use of selective serotonin-reuptake inhibitors and QT interval prolongation in newborns. Pediatrics 2008; 122 (3): e710-5.
11.
Faden J, Citrome L. Intravenous brexanolone for postpartum depression: what it is, how well does it work, and will it be used? Ther Adv Psychopharmacol 2020; 10: 2045125320968658.
12.
Food and Drug Administration, U. S. F. a. D. FDA approves first treatment for post-partum depression. Available at: https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-post-partum-depression (Accessed: March 18 2023.)
13.
Gentile S. Tricyclic antidepressants in pregnancy and puerperium. Expert Opin Drug Saf 2014; 13 (2): 207-25.
14.
Griffin LD, Mellon SH. Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes. Proc Natl Acad Sci U S A 1999; 96 (23): 13512-7.
15.
Grzeskowiak LE, McBain R, Dekker GA, Clifton VL. Antidepressant use in late gestation and risk of postpartum haemorrhage: a retrospective cohort study. Bjog 2016; 123 (12): 1929-36.
16.
Haase J, Brown E. Integrating the monoamine, neurotrophin and cytokine hypotheses of depression – a central role for the serotonin transporter? Pharmacol Ther 2015; 147: 1-11.
17.
Haim A, Albin-Brooks C, Sherer M, Mills E, Leuner B. The effects of gestational stress and Selective Serotonin reuptake inhibitor antidepressant treatment on structural plasticity in the postpartum brain – a translational model for postpartum depression. Horm Behav 2016; 77: 124-31.
18.
Hanley GE, Smolina K, Mintzes B, Oberlander TF, Morgan SG. Postpartum Hemorrhage and Use of Serotonin Reuptake Inhibitor Antidepressants in Pregnancy. Obstet Gynecol 2016; 127 (3): 553-61.
19.
Hantsoo L, Ward-O'Brien D, Czarkowski KA, Gueorguieva R, Price LH, Epperson CN. A randomized, placebo-controlled, double-blind trial of sertraline for postpartum depression. Psychopharmacology (Berl) 2014; 231 (5): 939-48.
20.
Hasler G, van der Veen JW, Tumonis T, Meyers N, Shen J, Drevets WC. Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. Arch Gen Psychiatry 2007; 64 (2): 193-200.
21.
Heinonen E, Blennow M, Blomdahl-Wetterholm M, Hovstadius M, Nasiell J, Pohanka A, Gustafsson LL, Wide K. Sertraline concentrations in pregnant women are steady and the drug transfer to their infants is low. Eur J Clin Pharmacol 2021; 77 (9): 1323-31.
22.
Howard LM, Molyneaux E, Dennis CL, Rochat T, Stein A, Milgrom J. Non-psychotic mental disorders in the perinatal period. Lancet 2014; 384 (9956): 1775-88.
23.
Hutcherson TC, Cieri-Hutcherson NE, Gosciak MF. Brexanolone for postpartum depression. Am J Health Syst Pharm 2020; 77 (5): 336-45.
24.
Johansen RL, Mortensen LH, Andersen AM, Hansen AV, Strandberg-Larsen K. Maternal use of selective serotonin reuptake inhibitors and risk of miscarriage – assessing potential biases. Paediatr Perinat Epidemiol 2015; 29 (1): 72-81.
25.
Kanes S, Colquhoun H, Gunduz-Bruce H, Raines S, Arnold R, Schacterle A, Doherty J, Epperson CN, Deligiannidis KM, Riesenberg R, Hoffmann E, Rubinow D, Jonas J, Paul S, Meltzer-Brody S. Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial. Lancet 2017a; 390 (10093): 480-89.
26.
Kanes SJ, Colquhoun H, Doherty J, Raines S, Hoffmann E, Rubinow DR, Meltzer-Brody S. Open-label, proof-of-concept study of brexanolone in the treatment of severe postpartum depression. Hum Psychopharmacol 2017b; 32 (2).
27.
Kessel JB, Simpson GM. Tricyclic and tetracyclic drugs. Comprehensive textbook of psychiatry. Philadelphia: Williams & Wilkins, 1995: 2096-112.
28.
Kim JY, Son MJ, Son CY, Radua J, Eisenhut M, Gressier F, Koyanagi A, Carvalho AF, Stubbs B, Solmi M, Rais TB., Lee KH, Kronbichler A, Dragioti E, Shin JI, and Fusar-Poli P. Environmental risk factors and biomarkers for autism spectrum disorder: an umbrella review of the evidence. Lancet Psychiatry 2019; 6 (7): 590-600.
29.
Krishnan V, Nestler EJ. The molecular neurobiology of depression. Nature 2008; 455 (7215): 894-902.
30.
Källén BA, Otterblad Olausson P. Maternal drug use in early pregnancy and infant cardiovascular defect. Reprod Toxicol 2003; 17 (3): 255-61.
31.
Latendresse G, Elmore C, Deneris A. Selective Serotonin Reuptake Inhibitors as First-Line Antidepressant Therapy for Perinatal Depression. J Midwifery Womens Health (2017); 62 (3): 317-28.
32.
Luscher B, Shen Q, Sahir N. The GABAergic deficit hypothesis of major depressive disorder. Mol Psychiatry 2011; 16 (4): 383-406.
33.
Lusskin SI, Khan SJ, Ernst C, Habib S, Fersh ME, Albertini ES. Pharmacotherapy for Perinatal Depression. Clin Obstet Gynecol 2018; 61 (3): 544-61.
34.
Meltzer-Brody S, Colquhoun H, Riesenberg R, Epperson CN, Deligiannidis KM, Rubinow DR, Li H, Sankoh AJ, Clemson C, Schacterle A, Jonas J and Kanes S. Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet (2018); 392 (10152): 1058-70.
35.
Molyneaux E, Telesia LA, Henshaw C, Boath E, Bradley E, Howard LM. Antidepressants for preventing postnatal depression. Cochrane Database Syst Rev 2018; 4 (4): Cd004363.
36.
Morales DR, Slattery J, Evans S, Kurz X. Antidepressant use during pregnancy and risk of autism spectrum disorder and attention deficit hyperactivity disorder: systematic review of observational studies and methodological considerations, BMC Med 2018; 16 (1): 6.
37.
National Collaborating Centre for Mental Health. Antenatal and Postnatal Mental Health: The NICE Guideline on Clinical Management and Service Guidance. In: National Institute for Health and Clinical Excellence: Guidance, Leicester (UK): British Psychological Society 2007, The British Psychological Society & The Royal College of Psychiatrists.
38.
O’Hara MW, McCabe JE. Postpartum depression: current status and future directions. Annu Rev Clin Psychol 2013; 9: 379-407.
39.
Oberlander TF, Misri S, Fitzgerald CE, Kostaras X, Rurak D, Riggs W. Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure. J Clin Psychiatry 2004; 65 (2): 230-7.
40.
Qiu W, Duarte-Guterman P, Eid RS, Go KA, Lamers Y, Galea LAM. Postpartum fluoxetine increased maternal inflammatory signalling and decreased tryptophan metabolism: Clues for efficacy. Neuropharmacology 2020; 175: 108174.
41.
Salari AA, Fatehi-Gharehlar L, Motayagheni N, Homberg JR. Fluoxetine normalizes the effects of prenatal maternal stress on depression- and anxiety-like behaviors in mouse dams and male offspring. Behav Brain Res 2016; 311: 354-67.
42.
Samochowiec J, Rybakowski J, Galecki P, Szulc A, Rymaszewska J, Cubała WJ, Dudek D. Recommendations of the Polish Psychiatric Association for treatment of affective disorders in women of childbearing age. Part I: Treatment of depression. Psychiatr Pol 2019, 53 (2): 245-62.
43.
Sanacora G, Gueorguieva R, Epperson CN, Wu YT, Appel M, Rothman DL, Krystal JH, Mason GF. Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Arch Gen Psychiatry 2004; 61 (7): 705-13.
44.
Sie SD, Wennink JM, van Driel JJ, te Winkel AG, Boer K, Casteelen G, van Weissenbruch MM. Maternal use of SSRIs, SNRIs and NaSSAs: practical recommendations during pregnancy and lactation. Arch Dis Child Fetal Neonatal Ed (2012); 97 (6): F472-6.
45.
Spielman FJ, Mueller RA, Corke BC. Cerebrospinal fluid concentration of 5-hydroxyindoleactic acid in pregnancy. Anesthesiology (1985); 62 (2): 193-5.
46.
Spina E, Trifirò G, Caraci F. Clinically significant drug interactions with newer antidepressants. CNS Drugs 2012; 26 (1): 39-67.
47.
Stewart DE, Vigod S. Postpartum Depression. N Engl J Med 2016; 375 (22): 2177-86.
48.
Stiskal JA, Kulin N, Koren G, Ho T, Ito S. Neonatal paroxetine withdrawal syndrome. Arch Dis Child Fetal Neonatal Ed 2001; 84 (2): F134-5.
49.
Suryawanshi O. 4th, Pajai S. A Comprehensive Review on Postpartum Depression. Cureus 2022; 14 (12): e32745.
50.
Ter Horst PG, Jansman FG, van Lingen RA., Smit JP, de Jong-van den Berg LT, Brouwers JR. Pharmacological aspects of neonatal antidepressant withdrawal. Obstet Gynecol Surv 2008; 63 (4): 267-79.
51.
Uguz F. Poor Feeding and Severe Sedation in a Newborn Nursed by a Mother on a Low Dose of Amitriptyline. Breastfeed Med 2017; 12: 67-8.
52.
Ulrich S, Ricken R, Buspavanich P, Schlattmann P, Adli M. Efficacy and Adverse Effects of Tranylcypromine and Tricyclic Antidepressants in the Treatment of Depression: A Systematic Review and Comprehensive Meta-analysis. J Clin Psychopharmacol 2020; 40 (1): 63-74.
53.
Weissman AM, Levy BT, Hartz AJ. Bentler S, Donohue M, Ellingrod VL, Wisner KL. Pooled analysis of antidepressant levels in lactating mothers, breast milk, and nursing infants. Am J Psychiatry 2004; 161 (6): 1066-78.
54.
Whitby DH, Smith KM. The use of tricyclic antidepressants and selective serotonin reuptake inhibitors in women who are breastfeeding. Pharmacotherapy 2005; 25 (3): 411-25.
55.
Wisner KL, Hanusa BH, Perel JM, Peindl KS, Piontek CM, Sit DK, Findling RL, Moses-Kolko EL. Postpartum depression: a randomized trial of sertraline versus nortriptyline. J Clin Psychopharmacol 2006; 26 (4): 353-60.
56.
Wisner KL, Sit DK, McShea MC, Rizzo DM, Zoretich RA, Hughes CL, Eng HF, Luther JF, Wisniewski SR, Costantino ML, Confer AL, Moses-Kolko EL, Famy CS, Hanusa BH. Onset timing, thoughts of self-harm, and diagnoses in postpartum women with screen-positive depression findings. JAMA Psychiatry 2013; 70 (5): 490-8.
57.
Zhao C, Gammie SC. Glutamate, GABA, and glutamine are synchronously upregulated in the mouse lateral septum during the postpartum period. Brain Res 2014; 1591: 53-62.
58.
Zheng W, Cai DB, Sim K, Ungvari GS, Peng XJ, Ning YP, Wang G, Xiang YT. Brexanolone for postpartum depression: A meta-analysis of randomized controlled studies. Psychiatry Res 2019; 279: 83-9.
59.
ZULRESSO® Safety Information. Available at: https://www.zulresso.com/about-zulresso/safety (Accessed: 3 February 2023.)
